Mesothelioma pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
[[Asbestos]] causes DNA damage directly by mechanically interfering with the segregation of [[chromosomes]] during [[mitosis]] and indirectly by inducing [[mesothelial cells]] and [[macrophages]], to release mutagenic [[reactive oxygen]] and nitrogen species.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> Asbestos fibres have been shown to alter the function and secretory properties of [[macrophages]], ultimately creating conditions which favor the development of mesothelioma. Following asbestos [[phagocytosis]], macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences. Genes involved in the pathogenesis of mesothelioma include ''[[BAP1]]'', ''[[CDKN2A]]'', ''[[WT1]]'', ''[[NF2 gene|NF2]]'', and ''[[TP53]]''.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref><ref name="pmid15950811">{{cite journal| author=Ladanyi M| title=Implications of P16/CDKN2A deletion in pleural mesotheliomas. | journal=Lung Cancer | year= 2005 | volume= 49 Suppl 1 | issue=  | pages= S95-8 | pmid=15950811 | doi=10.1016/j.lungcan.2005.03.017 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15950811  }} </ref><ref name="pmid9072005">{{cite journal| author=Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J et al.| title=WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. | journal=J Pathol | year= 1997 | volume= 181 | issue= 1 | pages= 67-74 | pmid=9072005 | doi=10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9072005  }} </ref><ref name="pmid22825583">{{cite journal| author=Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M et al.| title=New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. | journal=Clin Cancer Res | year= 2012 | volume= 18 | issue= 17 | pages= 4485-90 | pmid=22825583 | doi=10.1158/1078-0432.CCR-11-2375 | pmc=PMC3432735 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22825583  }} </ref><ref name="pmid23435014">{{cite journal| author=Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I et al.| title=Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. | journal=Mutagenesis | year= 2013 | volume= 28 | issue= 3 | pages= 323-31 | pmid=23435014 | doi=10.1093/mutage/get008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23435014  }} </ref><ref name="pmid18248818">{{cite journal| author=Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R et al.| title=PTEN expression is a strong predictor of survival in mesothelioma patients. | journal=Eur J Cardiothorac Surg | year= 2008 | volume= 33 | issue= 3 | pages= 502-6 | pmid=18248818 | doi=10.1016/j.ejcts.2007.09.045 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18248818  }} </ref><ref name="pmid21245096">{{cite journal| author=Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T et al.| title=LATS2 is a tumor suppressor gene of malignant mesothelioma. | journal=Cancer Res | year= 2011 | volume= 71 | issue= 3 | pages= 873-83 | pmid=21245096 | doi=10.1158/0008-5472.CAN-10-2164 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21245096  }} </ref> On gross pathology, pleural mesothelioma is characterized by discrete plaques and nodules that coalesce to produce a sheet-like tumor, with the pleural surface seeding of malignant mesothelioma cells.<ref name=epidemiologymesothelioma1>Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> Based on the '''histology''', mesothelioma may be classified into 3 subtypes: epithelial, sarcomatoid, and biphagic.<ref name=mesotheliomaclass1>Mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016</ref> Mesothelioma is demonstrated by positivity to [[tumor marker]]s, such as [[calretinin]], epithelial membrane antigen, [[cytokeratin]], and [[mesothelin]].<ref name=pathologymesotehelioma1>Pathology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 10, 2016</ref><ref name=ihcmesothelioma1>Immunohistochemistry of mesothelioma. Wikipedia 2016. https://en.wikipedia.org/wiki/Mesothelioma. Accessed on February 12, 2016</ref>
[[Asbestos]] causes DNA damage directly by mechanically interfering with the segregation of [[chromosomes]] during [[mitosis]] and indirectly by inducing [[mesothelial cells]] and [[macrophages]], to release mutagenic [[reactive oxygen]] and nitrogen species.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> Asbestos fibres have been shown to alter the function and secretory properties of [[macrophages]], ultimately creating conditions which favor the development of mesothelioma. Following asbestos [[phagocytosis]], macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences. Genes involved in the pathogenesis of mesothelioma include ''[[BAP1]]'', ''[[CDKN2A]]'', ''[[WT1]]'', ''[[NF2 gene|NF2]]'', and ''[[TP53]]''.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref><ref name="pmid15950811">{{cite journal| author=Ladanyi M| title=Implications of P16/CDKN2A deletion in pleural mesotheliomas. | journal=Lung Cancer | year= 2005 | volume= 49 Suppl 1 | issue=  | pages= S95-8 | pmid=15950811 | doi=10.1016/j.lungcan.2005.03.017 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15950811  }} </ref><ref name="pmid9072005">{{cite journal| author=Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J et al.| title=WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. | journal=J Pathol | year= 1997 | volume= 181 | issue= 1 | pages= 67-74 | pmid=9072005 | doi=10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9072005  }} </ref><ref name="pmid22825583">{{cite journal| author=Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M et al.| title=New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. | journal=Clin Cancer Res | year= 2012 | volume= 18 | issue= 17 | pages= 4485-90 | pmid=22825583 | doi=10.1158/1078-0432.CCR-11-2375 | pmc=PMC3432735 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22825583  }} </ref><ref name="pmid23435014">{{cite journal| author=Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I et al.| title=Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. | journal=Mutagenesis | year= 2013 | volume= 28 | issue= 3 | pages= 323-31 | pmid=23435014 | doi=10.1093/mutage/get008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23435014  }} </ref><ref name="pmid18248818">{{cite journal| author=Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R et al.| title=PTEN expression is a strong predictor of survival in mesothelioma patients. | journal=Eur J Cardiothorac Surg | year= 2008 | volume= 33 | issue= 3 | pages= 502-6 | pmid=18248818 | doi=10.1016/j.ejcts.2007.09.045 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18248818  }} </ref><ref name="pmid21245096">{{cite journal| author=Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T et al.| title=LATS2 is a tumor suppressor gene of malignant mesothelioma. | journal=Cancer Res | year= 2011 | volume= 71 | issue= 3 | pages= 873-83 | pmid=21245096 | doi=10.1158/0008-5472.CAN-10-2164 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21245096  }} </ref> On gross pathology, pleural mesothelioma is characterized by discrete plaques and nodules that coalesce to produce a sheet-like tumor, with the pleural surface seeding of malignant mesothelioma cells.<ref name=epidemiologymesothelioma1>Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> Based on the histology, mesothelioma may be classified into 3 subtypes: epithelial, sarcomatoid, and biphagic.<ref name=mesotheliomaclass1>Mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016</ref> Mesothelioma is demonstrated by positivity to [[tumor marker]]s, such as [[calretinin]], epithelial membrane antigen, [[cytokeratin]], and [[mesothelin]].<ref name=pathologymesotehelioma1>Pathology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 10, 2016</ref><ref name=ihcmesothelioma1>Immunohistochemistry of mesothelioma. Wikipedia 2016. https://en.wikipedia.org/wiki/Mesothelioma. Accessed on February 12, 2016</ref>


==Pathogenesis==
==Pathogenesis==

Revision as of 20:32, 15 February 2016

Mesothelioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mesothelioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Summary of Treatment for Pleural Mesothelioma

Summary of Treatment for Peritoneal Mesothelioma

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mesothelioma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mesothelioma pathophysiology

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mesothelioma pathophysiology

CDC on Mesothelioma pathophysiology

Mesothelioma pathophysiology in the news

Blogs on Mesothelioma pathophysiology

Directions to Hospitals Treating Mesothelioma

Risk calculators and risk factors for Mesothelioma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Sujit Routray, M.D. [3]

Overview

Asbestos causes DNA damage directly by mechanically interfering with the segregation of chromosomes during mitosis and indirectly by inducing mesothelial cells and macrophages, to release mutagenic reactive oxygen and nitrogen species.[1] Asbestos fibres have been shown to alter the function and secretory properties of macrophages, ultimately creating conditions which favor the development of mesothelioma. Following asbestos phagocytosis, macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences. Genes involved in the pathogenesis of mesothelioma include BAP1, CDKN2A, WT1, NF2, and TP53.[1][2][3][4][5][6][7] On gross pathology, pleural mesothelioma is characterized by discrete plaques and nodules that coalesce to produce a sheet-like tumor, with the pleural surface seeding of malignant mesothelioma cells.[8] Based on the histology, mesothelioma may be classified into 3 subtypes: epithelial, sarcomatoid, and biphagic.[9] Mesothelioma is demonstrated by positivity to tumor markers, such as calretinin, epithelial membrane antigen, cytokeratin, and mesothelin.[10][11]

Pathogenesis

  • Asbestos causes DNA damage directly by mechanically interfering with the segregation of chromosomes during mitosis and indirectly by inducing mesothelial cells and macrophages, to release mutagenic reactive oxygen and nitrogen species.[1] Asbestos fibres have been shown to alter the function and secretory properties of macrophages, ultimately creating conditions which favor the development of mesothelioma. Following asbestos phagocytosis, macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences.
  • The mesothelium consists of a single layer of flattened to cuboidal cells forming the epithelial lining of the serous cavities of the body including the peritoneal, pericardial and pleural cavities. Deposition of asbestos fibres in the parenchyma of the lung may result in the penetration of the visceral pleura from where the fibre can then be carried to the pleural surface, thus leading to the development of malignant mesothelial plaques. The processes leading to the development of peritoneal mesothelioma remain unresolved, although it has been proposed that asbestos fibres from the lung are transported to the abdomen and associated organs via the lymphatic system. Additionally, asbestos fibres may be deposited in the gut after ingestion of sputum contaminated with asbestos fibres.
  • Asbestos also may possess immunosuppressive properties. For example, chrysotile fibres have been shown to depress the in-vitro proliferation of phytohemagglutinin-stimulated peripheral blood lymphocytes, suppress natural killer cell lysis, and significantly reduce lymphokine-activated killer cell viability and recovery. Furthermore, genetic alterations in asbestos-activated macrophages may result in the release of potent mesothelial cell mitogens such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β) which in turn, may induce the chronic stimulation and proliferation of mesothelial cells after injury by asbestos fibres.

Genetics

  • Asbestos has also been shown to mediate the entry of foreign DNA into target cells. Incorporation of this foreign DNA may lead to mutations and oncogenesis, by several possible mechanisms:

Gross Pathology

  • On gross pathology, pleural mesothelioma is characterized by discrete plaques and nodules that coalesce to produce a sheet-like tumor, with the pleural surface seeding of malignant mesothelioma cells.[8]
  • The growth usually starts at the inferior margins of the pleura and may invade the diaphragm.
  • The lung and interlobar fissures may also be involved.[8]

Gallery

  • Mesothelioma completely encasing the lung.<ref name=grosspictureofmesotheliomaimage1>Image courtesy of Dr. Yale Rosen. Radiopaedia (original file here). Creative Commons BY-SA-NC

    Mesothelioma completely encasing the lung.<ref name=grosspictureofmesotheliomaimage1>Image courtesy of Dr. Yale Rosen. Radiopaedia (original file here). Creative Commons BY-SA-NC

Microscopic Pathology

Based on the histology, mesothelioma may be classified into 3 subtypes:[9]

  • Epithelial
  • Sarcomatoid
  • Biphasic (mixed)

Immunohistochemistry

  • The cytological and histological diagnosis can be difficult, with mesothelial hyperplasia and metastatic adenocarcinoma appearing similar. Specific markers may be helpful in the diagnosis of mesothelioma.[10]
  • Mesothelioma is demonstrated by positivity to tumor markers, such as:[10][11]

References

  1. ↑ 1.0 1.1 1.2 1.3 Thomas, Anish; Chen, Yuanbin; Yu, Tinghui; Gill, Ammara; Prasad, Vinay (2015). "Distinctive clinical characteristics of malignant mesothelioma in young patients". Oncotarget. 6 (18): 16766–16773. doi:10.18632/oncotarget.4414. ISSN 1949-2553.
  2. ↑ 2.0 2.1 Ladanyi M (2005). "Implications of P16/CDKN2A deletion in pleural mesotheliomas". Lung Cancer. 49 Suppl 1: S95–8. doi:10.1016/j.lungcan.2005.03.017. PMID 15950811.
  3. ↑ 3.0 3.1 Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J; et al. (1997). "WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis". J Pathol. 181 (1): 67–74. doi:10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z. PMID 9072005.
  4. ↑ 4.0 4.1 Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M; et al. (2012). "New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment". Clin Cancer Res. 18 (17): 4485–90. doi:10.1158/1078-0432.CCR-11-2375. PMC 3432735. PMID 22825583.
  5. ↑ 5.0 5.1 Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I; et al. (2013). "Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma". Mutagenesis. 28 (3): 323–31. doi:10.1093/mutage/get008. PMID 23435014.
  6. ↑ 6.0 6.1 Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R; et al. (2008). "PTEN expression is a strong predictor of survival in mesothelioma patients". Eur J Cardiothorac Surg. 33 (3): 502–6. doi:10.1016/j.ejcts.2007.09.045. PMID 18248818.
  7. ↑ 7.0 7.1 Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T; et al. (2011). "LATS2 is a tumor suppressor gene of malignant mesothelioma". Cancer Res. 71 (3): 873–83. doi:10.1158/0008-5472.CAN-10-2164. PMID 21245096.
  8. ↑ 8.0 8.1 8.2 Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016
  9. ↑ 9.0 9.1 Mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016
  10. ↑ 10.0 10.1 10.2 Pathology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 10, 2016
  11. ↑ 11.0 11.1 Immunohistochemistry of mesothelioma. Wikipedia 2016. https://en.wikipedia.org/wiki/Mesothelioma. Accessed on February 12, 2016


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Mesothelioma_pathophysiology&oldid=1216340"